Skip to main
SOLV
SOLV logo

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 63%
Sell 0%
Strong Sell 13%

Bulls say

Solventum Corp demonstrates a positive growth outlook through its commitment to market development, particularly within its MedSurg segment, which dominates revenue generation by enhancing healing methods and reducing overall healthcare costs. The company's strategy includes accelerating the global adoption of its antimicrobial solutions and improving the standard of care, which positions it strongly within the healthcare sector. Additionally, significant growth is anticipated in the Revenue Cycle Management segment due to expanded capabilities, continuous product innovation, and a strategic shift toward autonomous coding and international markets.

Bears say

Solventum Corp has faced a significant challenge, evidenced by seven consecutive quarters of negative volume growth prior to its spin-off, indicating a persistent decline in demand for its products. The company is projected to experience further financial strain, with an anticipated gross margin decline of approximately 40 basis points in 2026, largely attributed to the impact of tariffs. These fundamental issues suggest underlying operational weaknesses and potential instability in revenue generation, raising concerns about the company's future financial performance.

Solventum Corporation (SOLV) has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 63% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Hold based on their latest research and market trends.

According to 8 analysts, Solventum Corporation (SOLV) has a Hold consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.